Bobcat mRNA works differently than exon skipping or AAV-microdystrophy mechanisms. This next-generation method could lead to low-cost drugs for Duchenne muscular dystrophy.
Many exon skipping...
Next generation exon skipping therapies for Duchenne Muscular Dystrophy (DMD) represent a promising area of research aimed at addressing the underlying genetic mutations that...
Insmed is getting ready to use its ground-breaking gene therapy, INS1201, to combat Duchenne muscular dystrophy. Insmed intends to start Phase I clinical trials...
We are happy to present the winners of the American Neuromuscular Foundation's (ANF) 2024 Investigator Grant Award. Liubov Gushchina, PhD, received the prize for...